Spur Therapeutics
↗London, United Kingdom
Spur Therapeutics (formerly Freeline Therapeutics) is a clinical-stage gene therapy company focused on developing transformative AAV-based therapies for serious chronic diseases including rare genetic disorders and more prevalent conditions. Founded in 2015 as a UCL spinout in collaboration with Syncona, Freeline developed a proprietary AAV vector platform with rationally designed capsids and novel promoters. In June 2024, Syncona orchestrated the merger of Freeline with SwanBio Therapeutics to create Spur Therapeutics, expanding the pipeline to include programs in neurodegenerative diseases and cardiovascular conditions. The company is now 99% owned by Syncona with an additional $50 million committed for pipeline development.
CLASSIFICATION
SIZE & FINANCIALS
Employees:201-500
Founded:2015
Ownership:subsidiary
Status:acquired
FUNDING
Stage:Private
Total Raised:$274M
Investors:Syncona (major investor and current owner), Novo Holdings, Eventide Asset Management, Wellington Management Company, The UCL Technology Fund, Mass General Brigham Ventures
STOCK
Ticker:FRLN (delisted from NASDAQ after acquisition)
PIPELINE
Stage:Phase 1/2 to Phase 3
Lead Drug Stage:Phase 1/2 to Phase 3 initiation (FLT201)
Modalities:AAV Gene Therapy, AAVS3 Vector, Intrathecal delivery
Active Trials:2
Trial Phases:Phase 1: 2 | Phase 2: 2
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Parent Company:Syncona Portfolio Limited
Acquired By:Syncona Portfolio Limited (2024-02-01)
Key Partnerships:Forcefield Therapeutics: AAV gene therapies for cardiac conditions; Freeline gained development and commercialization rights
COMPETITION
Position:Emerging
Competitors:Spark Therapeutics, Avrobio, UniQure, CSL Behring, Sanofi (via fitusiran), Pfizer (via marstacimab), Novo Nordisk (via Mim8), Roche (via SPK-8011 through Spark Therapeutics) +3 more
LEADERSHIP
Key Executives:
Michael Parini - Chief Executive Officer
Chris Hollowood - Chairman
John Tsai - Board Member
Amit Nathwani - Founder, Clinical and Scientific Adviser
Brian Silver - Chief Financial Officer & Head of Corporate Development
Henning R. Stennicke - Chief Scientific Officer
Scientific Founders:Prof. Amit Nathwani (UCL Faculty of Medical Sciences)
Board Members:Chris Hollowood, John Tsai, Michael Parini
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Spur Therapeutics. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.